New Delhi, June 23 -- Danish drugmaker Novo Nordisk A/S said on Monday it is terminating a recently formed obesity-drug partnership with Hims & Hers Health Inc, citing concerns about sales of compounded drugs and misleading marketing.

The partnership had been touted as a way to boost obesity-drug sales in the US.

Shares of Hims & Hers plunged 18% in trading before US stock exchanges opened. Novo lost as much as 5% in Copenhagen.

Published by HT Digital Content Services with permission from MINT....